Viridian Therapeutics, Inc.\de balance sheet

At the end of fiscal 2025, Viridian Therapeutics, Inc.\de had total assets of $899m, total liabilities of $177m and shareholders' equity of $722m. It held $212m in cash against $49.9m of debt: net cash of $162m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Viridian Therapeutics, Inc.\de: balance sheet, annual
Fiscal year	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash and equivalents	0	5	21	22	47	33	25	46	42	156	103	100	212	165
Receivables	1	1	0	0	1	0	0	—	—	—	—	—	—	—
Inventory	0	0	0	0	—	—	—	—	—	—	—	—	—	—
Total current assets	2	7	12	24	52	65	30	130	200	431	486	738	894	1,081
Total assets	4	8	13	25	52	66	30	131	204	435	490	742	899	1,097
Accounts payable	0	0	0	1	1	1	1	1	2	14	2	2	9	9
Deferred revenue (current)	—	—	—	—	—	—	0	0	0	0	0	0	0	0
Total current liabilities	27	2	2	7	4	7	10	11	14	33	27	48	71	64
Short-term debt	—	—	—	—	—	—	—	—	—	—	0	0	—	—
Long-term debt	—	—	—	3	10	10	8	0	0	5	20	21	0	242
Total debt	0	0	0	5	10	12	12	0	0	5	20	21	50	242
Total liabilities	—	—	—	10	14	15	15	11	16	40	48	71	177	435
Shareholders' equity	−24	6	−45	−62	39	51	16	120	188	395	442	672	722	662
Non-controlling interests and other (assets − liabilities − equity)	—	—	—	77	—	—	—	—	—	—	—	—	—	—
Net debt (negative = net cash)	−0	−5	−21	−17	−37	−20	−13	−46	−42	−151	−83	−79	−162	77
Shares outstanding	—	—	—	—	—	—	2m	4m	—	—	54m	81m	102m	113m

US$ millions unless shown otherwise. Fiscal quarters.

Viridian Therapeutics, Inc.\de: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Total current assets	767	738	657	579	572	894	785	1,081
Total assets	772	742	661	582	577	899	789	1,097
Accounts payable	6	2	4	9	10	9	13	9
Deferred revenue (current)	0	0	0	0	0	0	0	0
Total current liabilities	41	48	34	53	51	71	52	64
Short-term debt	—	0	—	8	—	—	—	—
Long-term debt	21	21	21	12	21	0	—	242
Total debt	21	21	21	21	21	0	—	242
Total liabilities	64	71	57	67	74	177	153	435
Shareholders' equity	707	672	604	515	503	722	636	662
Shares outstanding	79m	81m	82m	82m	82m	102m	102m	113m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: VRDN vs WVE CGEN vs VRDN RXRX vs VRDN ASMB vs VRDN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Viridian Therapeutics, Inc.\de's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Viridian Therapeutics, Inc.\de.